BGLC — Q2 2026 Financial Report Analysis

Overview

BioNexus Gene Lab (Nasdaq: BGLC) is a small Malaysia-based holding company with two operating units: Chemrex, an industrial-chemicals wholesaler that used to supply almost all of its revenue, and MRNA Scientific, a blood-based genetic screening lab. In the quarter to June 30, 2026, revenue fell 96.6% to $76,156 from $2.26 million a year earlier. The 10-Q blames Chemrex's collapse on "the actions of former management which occurred during the course of fiscal year 2025"; in May 2026 the company sent letters of demand to five former Chemrex officers and directors for about $2.94 million it alleges they caused to be paid out of Chemrex's accounts between July 2024 and August 2025 (not yet tested in court, and no proceeding has been filed). The net loss nonetheless narrowed 53.5% to $286,451, because Chemrex's sales staff and overheads were cut faster than its revenue fell.

All figures are in US dollars (the company reports in USD, translating from Malaysian ringgit) and in whole dollars, not millions: this is a company with a quarterly revenue smaller than many households' annual income.

At a glance

• Revenue $76,156 (-96.6%) — the chemicals business that produced $2.26 million a year ago is now a fraction of its former size; the genetic-screening lab contributed just $650.
• Net loss $286,451, down from $616,172 — the improvement comes from cost cuts, not from the business earning more: gross profit (sales minus the direct cost of the goods sold) was only $12,982.
• Cash and fixed deposits $3.52 million at June 30 — versus a six-month operating cash outflow of $570,162 and roughly $1.42 million still owed over time on a $2 million licence for a cancer-monitoring test.

Results

For the first half, revenue was $98,998 (down 97.7% from $4.40 million) and the net loss was $830,026 (versus $1.24 million). The second quarter was better than the first: revenue more than tripled from about $22,800 in Q1 to $76,156, and the quarterly loss fell from $543,575 to $286,451. Management says Chemrex's "core trading activity and gross margin improved sequentially", with Chemrex's gross margin at 17.1% in Q2 against 11.8% for the half — but the starting point is very low.

Why costs fell. Sales and marketing expense dropped 94% to $36,022; the filing attributes Chemrex's 99.95% cut to "lower associated staff remuneration as a result of the change in management and reduction in variable selling expenses." General and administrative expense fell 42% to $298,526, mainly lower Chemrex salaries and office costs, plus 11% lower parent-company professional fees. EPS improved more than the net loss because the share count rose by about a third: 2,417,314 weighted shares versus 1,796,597, after shares issued in late 2025 for the Fidelion deal, an equity-line commitment fee and at-the-market sales.

What the headline numbers hide

• The "operating" loss includes non-operating income. BioNexus places other income ($121,005) above operating expenses, so its reported loss from operations is flattered. Of that, $91,383 was a reversal of earlier bad-debt provisions as old Chemrex receivables were collected, and $21,183 was interest on deposits. A separate $68,164 new bad-debt provision sits in expenses. Stripping both credit-loss lines out, the underlying operating loss was about $305,600 — and the business's cost base (sales, R&D and admin: about $348,000) was roughly 27 times its gross profit. Management itself warns that "collections and recovered credit losses should not be viewed as recurring trading revenue."
• Bad debts are still building. For the half, new credit-loss provisions were $270,661 against $118,126 of reversals. The allowance for unpaid customer bills rose to $849,330 while net trade receivables fell to just $15,544 — most of what customers still owe Chemrex has been written down as doubtful.
• Cash burn looks lower than the loss only because of collections and unpaid bills. Operating cash outflow for the half was $570,162 against a net loss of $830,026. That gap was helped by $310,559 collected from old receivables and a $212,487 rise in payables — almost all of it ($212,998) the increase in unpaid licence instalments owed to Fidelion, which stood at $296,331. Neither of these repeats indefinitely.
• A $2 million licence that is not yet on the books as an asset. In November 2025 BioNexus licensed the VitaGuard cancer "minimal residual disease" test (a blood test to detect cancer traces left after treatment) for the ASEAN region from Fidelion Diagnostics, for $2 million in 24 monthly instalments. Instalments so far are carried as $583,331 of prepaid "other assets"; the license itself has not been recognised as an intangible asset. Fidelion is a related party: BioNexus's CEO holds shares in it and is its CEO-designate. VitaGuard had produced no revenue by June 30.
• Internal controls are flagged as not effective. Management concluded both disclosure controls and internal control over financial reporting were not effective, citing a material weakness at Chemrex (approval authority, documentation, timely reporting) that the auditor had raised in 2024 and 2025. Review of the affected transactions "remains ongoing."
• No tax or buyback effects — there was no tax charge in either year, so the per-share improvement is cost cuts partly offset by a larger share count.

After the quarter: dilution and new deals

• $800,000 in stock awards to insiders. On August 13, 2026 the board issued 516,128 fully vested shares (valued at $1.55 each, $799,998) as bonuses "for completed services": 338,709 to the CEO, 96,774 to the CFO and the rest to three independent directors. That lifted the share count 21% to 2,933,442, and the expense is close to the company's entire first-half net loss. It will show up in Q3 results.
• A higher-cost CEO contract. The CEO was reappointed through August 2029 at a base salary of $35,000 a month ($420,000 a year) — more than four times the company's first-half revenue.
• Another share-funded licence. On October 5, 2026 BioNexus agreed to license the CogniAI document-AI platform for Malaysian healthcare from Ruanyun Edai Technology (Nasdaq: RYET), paying with 410,000 new shares (a stated $3.5 million licence value, which the filing notes "is not a statement of fair value") plus 150,000 more shares swapped for 500,000 RYET shares. If it closes, those 560,000 shares would be about 16% of the enlarged share count. Closing is subject to technology acceptance and due diligence, with a March 31, 2027 long-stop date.

Takeaway: The narrower loss is a cost-cutting story, not a recovery: the chemicals business that funded the company has shrunk to about $75,000 a quarter, the genetic-testing side brings in almost nothing, and the plan now rests on licensed products (VitaGuard, CogniAI) paid for with cash instalments and new shares — while insiders were just awarded stock worth about as much as the company lost in the whole first half.

Outlook

Management gave no revenue or earnings guidance. Its stated priorities are rebuilding Chemrex's customer base (and possibly moving it into contract manufacturing, which the board has authorised exploring but not committed to), launching VitaGuard in Southeast Asia once laboratory, validation and regulatory work is done, and releasing a rebuilt version of its blood-screening reporting system targeted for Q3 2026. It says cash on hand plus a $20 million at-the-market share-sale program with Maxim Group is enough for at least 12 months; it also has a $500 million equity line with ARC Group that it can draw at its discretion, subject to the agreement's terms.

Our read: on the numbers in this filing, cash is not the near-term problem — $3.52 million in cash and deposits is roughly three years of the first half's operating cash burn — but the burn is set to rise from Q3, with the $35,000-a-month CEO salary, about $83,000 a month in remaining Fidelion instalments, and the one-off $800,000 stock-award charge. Any return to meaningful revenue depends on VitaGuard actually launching, for which the company gives no date. Things to watch in the Q3 10-Q: whether Chemrex revenue keeps rising from Q2's level, the first VitaGuard revenue (if any), progress on recovering the $2.94 million from former Chemrex managers, and how many more shares are issued through the ATM, the ARC line and the CogniAI deal.